CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Endpoints News
Original article

Scynexis' BARDA alliance; Bristol Myers' early data for dual-targeting CAR-T

PartnershipSCY-247Positive
AI Analysis

Summary

Scynexis secured a $200M+ BARDA partnership for SCY-247, an investigational treatment for serious drug-resistant fungal infections. Bristol Myers Squibb disclosed early data for a dual-targeting CAR-T therapy.

Importance:7/10
Sentiment:
0.60
BARDApartnershipfungal_infectionsSCY-247CAR-T
Related Companies

Read the original article

Published by Endpoints News on September 28, 2026 3:22 PM

Read Original